LAURUSLABS - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | LAURUSLABS | Market Cap | 53,133 Cr. | Current Price | 984 ₹ | High / Low | 1,141 ₹ |
| Stock P/E | 66.4 | Book Value | 91.1 ₹ | Dividend Yield | 0.12 % | ROCE | 9.47 % |
| ROE | 7.75 % | Face Value | 2.00 ₹ | DMA 50 | 1,018 ₹ | DMA 200 | 915 ₹ |
| Chg in FII Hold | 0.35 % | Chg in DII Hold | 0.70 % | PAT Qtr | 175 Cr. | PAT Prev Qtr | 216 Cr. |
| RSI | 42.5 | MACD | -8.40 | Volume | 12,03,560 | Avg Vol 1Wk | 20,87,679 |
| Low price | 517 ₹ | High price | 1,141 ₹ | PEG Ratio | -2.86 | Debt to equity | 0.37 |
| 52w Index | 74.8 % | Qtr Profit Var | 206 % | EPS | 14.8 ₹ | Industry PE | 27.6 |
📊 Analysis: Laurus Labs shows weak momentum for intraday trading today. RSI at 42.5 indicates oversold territory but not yet a strong reversal signal. MACD is negative (-8.40), suggesting bearish momentum. Current price (984 ₹) is below the 50 DMA (1,018 ₹), showing short-term weakness, though above the 200 DMA (915 ₹), which provides medium-term support. Volume is lower than the 1-week average, indicating reduced participation.
💡 Optimal Buy Price: Around 975–980 ₹ if intraday support holds.
🎯 Profit Exit Levels: 995 ₹ (first target), 1,010 ₹ (second target if momentum improves).
⚠️ Stop-Loss: 965 ₹ to protect against downside risk.
📌 If Already Holding: Consider exiting near 995–1,010 ₹ if momentum indicators show weakness. If price falls below 965 ₹ with volume confirmation, exit to avoid deeper losses.
✅ Positive
- Strong quarterly profit variation (206%).
- EPS at 14.8 ₹ shows earnings stability.
- FII and DII holdings increased, indicating institutional confidence.
⚠️ Limitation
- High P/E (66.4) compared to industry average (27.6).
- Low ROE (7.75%) and ROCE (9.47%) suggest weak capital efficiency.
- Volume below average, limiting intraday momentum.
📉 Company Negative News
- Sequential decline in PAT (175 Cr. vs 216 Cr. previous quarter).
- MACD and RSI indicate weak short-term momentum.
📈 Company Positive News
- Strong YoY profit growth (206%).
- Institutional investors increasing stake.
- Debt-to-equity ratio at 0.37, manageable leverage.
🏭 Industry
- Pharma sector trading at PE ~27.6, Laurus Labs is overvalued relative to peers.
- Sector rotation may favor defensive pharma stocks, but valuation risk persists.
🔎 Conclusion
Laurus Labs is not an ideal intraday candidate today due to weak momentum and below-average volume. A cautious buy near 975–980 ₹ with tight stop-loss at 965 ₹ may work for scalpers, but risk-reward is limited. Better suited for swing trades if momentum improves above 1,018 ₹ (50 DMA).
Would you like me to also prepare a basket overlay with peer pharma stocks (like Divi’s Labs, Cipla, Sun Pharma) so you can benchmark Laurus Labs intraday strength against sector leaders?